About Us

The Management Team & Scientific Advisors

The Management Team

Agalimmune is led by experienced entrepreneurs and leading scientists with a wealth of expertise in developing and commercialising innovative technologies and products to improve the field of medicine:



Dr Chris Martin, Non-Executive Chairman

Dr. Chris Martin was co-founder of Spirogen Ltd and its Chief Executive Officer leading up to the sale of Spirogen to MedImmune, the global biologics research and development arm of Astra Zeneca in October 2013, for $440 million in upfront and deferred consideration. Dr.Martin continued as CEO of Spirogen, and became both a member of Medimmune’s Management Leadership Team and AstraZeneca’s Senior Leaders Group. Dr. Martin continues to advise Medimmune as a consultant.

Dr. Martin played an important role in the formation of ADC Therapeutics in 2012, and has served on its board of directors since its founding, and recently become the CEO of ADC Therapeutics. He is a recognised leader in the Antibody Drug Conjugates space, and his leadership of Spirogen led to Spirogen being awarded the Best Scientific Innovation Award in 2014 and Dr Martin being voted by industry peers the winner of the overall ‘Individual Input to the Industry in 2013/2014’ at the World ADC Awards.

Dr. Martin became Non-Executive Chairman of Agalimmune Ltd, a UK-based company developing immuno-oncology therapeutics using hyperacute rejection of cancer tissue causing personalized anti-tumour responses, in July 2015.


 Damian Marron, CEO

Damian is an accomplished CEO and non-executive director with a successful track record of value creation and leadership in public and private biotechnology companies, notably in the niche/orphan disease marketplace. One company, Trophos has been acquired for up to EUR700M and has raised well in excess of EUR200M in equity and non-dilutive financing.

Prior to Agalimmune, Damian was CEO of TxCell, a T-cell immunotherapy company, from September 2013 to April 2015, where he led a successful IPO in April 2014 on the Paris Euronext exchange.  Damian was CEO of Trophos SA from 2008 to 2012 where he positioned Trophos to be subsequently acquired by Roche for €700M. During his tenure attracted EUR 34 million in funding enabling Trophos to complete its clinical programs with success in Spinal Muscular Atrophy. Damian was also CEO of Cytheris SA 2012-2013, a clinical stage biotechnology company focused on immunology through the development of IL-7 based therapeutics in orphan and niche indications.  Prior to Trophos, he was Executive Vice President Corporate Development at NicOx SA for six years, where he was responsible for the establishment of major collaborations with Merck and Co. Inc. and Pfizer Inc and played a key role in financing rounds raising over EUR 175 million. Previously, Damian held various business development and operational roles at 3M Pharmaceuticals, Orphan Europe, Rhone-Poulenc-Rorer and Glaxo. Damian qualified in pharmacology with post-graduate experience in cell biology.


Graham Griffiths, Chief Operating Officer

Graham is an experienced director of early stage life sciences companies. He originally qualified as a solicitor in 2005 before moving into investment fund management and the development of early stage technology companies. He has extensive experienced in the operational and commercial management of life sciences companies, with 8 years of clinical development experience and two product launches. 

Scientific Advisors


Professor Uri Galili, Inventor

Uri Galili is an immunologist who received his PhD in 1977 at the Hebrew University, Jerusalem, Israel. He found the anti-Gal antibody in 1983 while working at Hadassah Hospital and continued his research on this antibody at the University of California, San Francisco in 1984. Professor Galili subsequently studied possible uses of this antibody in clinical settings and its role in xenograft rejection at MCP-Hahnemann Medical School and Rush Medical School. He then worked at the University of Massachusetts Medical School where he studied anti-Gal mediated conversion of tumors into autologous vaccines and anti-Gal mediated acceleration of wound healing, and invented the immunotherapeutic technology underlying Alphaject™. He has since retired from the University of Massachusetts and is now a Scientific Advisor to Agalimmune.